The efficacy of a second-generation derivative, omaveloxolone (RTA408), has recently been assessed in a preclinical model for diabetic chronic non-healing wounds [277] and, interestingly, omaveloxolone is now being tested in phase-II clinical trial for the Friedreichs ataxia (FRDA), a neurodegenerative condition in which NRF2 activation is suppressed [278, 279]
doi: 10.3389/fendo.2024.1429884 Received 08 May 2024 Accepted 28 May 2024 Published 19 June 2024 Volume 15 - 2024 Edited by Mariacarolina Salerno, University of Naples Federico II, Italy Reviewed by Malgorzata Gabriela Wasniewska, University of Messina, Italy Marek Niedziela, Poznan University of Medical Sciences, Poland Updates Copyright 2024 Street, Shulhai, Petraroli, Patianna, Donini, Giudice, Gnocchi, Masetti, Montani, Rotondo, Bernasconi, Iughetti, Esposito and Predieri
Community protocols describe injecting on an empty stomach food (especially carbs and fats) blunts the GH pulse
The researchers also explored the interaction of IgG mut-B2 with the TSP-1 domain of CTGF
